AN2 Therapeutics, Inc.
ANTXHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeAN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The $137.0M market capitalization puts ANTX squarely in micro-cap range for its industry. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis.
Market Cap
$137.0M
Beta
-0.98
P/E (TTM)
—
P/E (Fwd)
-4.54
EPS (TTM)
$-1.05
EPS (Fwd)
$-0.80
ROE
-50.1%
ROA
-30.8%
Cash
$78.4M
Total Debt
$0
Free CF
-$18.0M
52W Change
168.9%
Annual Financials
Cash vs Debt
Where ANTX stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, ANTX finished 28.45% below its 150-day moving average ($4.71) and 14.68% below its 200-day moving average ($3.95). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ANTX overbought or oversold?
At the October 20, 2026 close, ANTX's RSI(14) was 22.1, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
AN2 Therapeutics, Inc. reports $78.4M in cash and $0 in total debt. Free cash flow is running at -$18.0M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -50.1% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The relatively low beta of -0.98 suggests ANTX is a less volatile holding compared to the broader index. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing ANTX's risk profile alongside its fundamentals and technical indicators provides a more complete picture.